{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-24-000058","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.630834+00:00","generated_at":"2026-05-31T09:23:56.034424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LENZ Therapeutics files NDA for LNZ100, reports Q2 net loss $10.3M, raises $30M via PIPE","bullets":["NDA submitted to FDA for LNZ100 aceclidine eye drop for presbyopia, supported by positive Phase 3 CLARITY data.","Q2 net loss $10.3M ($0.40/share) vs $14.7M ($7.53) in Q2 2023; R&D expenses fell to $6.9M from $12.6M.","Cash, equivalents and securities $196.2M; pro forma after July $30M Ridgeback PIPE, $226.2M, expected to fund to post-launch positive cash flow.","Phase 3 CLARITY: LNZ100 71% achieved 3-line near vision improvement at 3 hours, 40% at 10 hours, well-tolerated over 30,000 patient days.","SG&A expenses rose to $7.4M from $2.3M on pre-commercial planning and public company costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-24-000058","json":"https://secwatch.observer/filing/0001815776-24-000058.json","markdown":"https://secwatch.observer/filing/0001815776-24-000058.md","text":"https://secwatch.observer/filing/0001815776-24-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/0001815776-24-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000058/lenz-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:56.034424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}